"GLP-1 medications are intriguing from a cancer research perspective because they weren't designed for cancer therapy, but they do affect many different targets and pathways associated with cancer development, so we're eager to study them in this context," McDonald said
4.3 Renal protection The use of GLP-1 receptor agonists has been shown to have substantial protective benefits on the kidneys, especially in cases of newly developed severe albuminuria
Monitoring Protocols Vital Signs: Blood pressure and heart rate tracking at each visit (GLP-1 agonists may slightly increase heart rate)
Additionally, the reduction in inflammatory markers that tirzepatide produces (C-reactive protein, IL-6, TNF-alpha) further supports NO bioavailability
Society for Experimental Biology and Medicine (New York, N.Y.) vol
Canada Latin America Brazil Argentina Mexico Rest of Latin America Europe Germany U.K